Pharmaceutical company Pfizer has announced its coronavirus vaccine candidate is more than 90% effective in preventing Covid-19 during an important trial. The firm is developing the mRNA-based vaccine with BioNTech and said the results were from a independent interim analysis of the results. The results far exceed the US Food and Drug Administration’s criteria for approving a Covid-19 vaccine, which mandates an efficacy of at least 50 per cent in placebo-controlled trials. This could make the shot available for use by the end of the year if drug authorities approve it. Pfizer boss Albert Bourla said the result was “a great day for science and humanity”. Up to 50 million doses of the vaccine could be manufactured this year, and a further 1.3 billion doses will be produced in 2021.
“I believe this is likely the most significant medical advance in the last 100 years, if you count the impact this will have in public health, global economy,” Dr. Albert Bourla told media. The coronavirus pandemic has claimed over 1.2 million lives worldwide. Pfizer and BioNTech said that there haven’t been any serious safety concerns reported yet. Pfizer’s vaccine requires a storage temperature of minus 94 degrees Fahrenheit. President Trump and President-elect Joe Biden both celebrated the news that the coronavirus vaccine being developed by Pfizer and BioNTech is successful.